Reply to "successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients-A Czech multicenter experience": A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era.

MLA

Cassin, Ramona, et al. “Reply to ‘Successful Early Use of Anti-SARS-CoV-2 Monoclonal Neutralizing Antibodies in SARS-CoV-2 Infected Hematological Patients-A Czech Multicenter Experience’: A Case Series of SARS-CoV-2 Omicron Infection and Aggressive Lymphoma in the Sotrovimab Era.” Hematological Oncology, vol. 41, no. 1, Feb. 2023, pp. 213–17. EBSCOhost, https://doi.org/10.1002/hon.3079.

APA

Cassin, R., Rampi, N., Anna Fidanza, C., Muscatello, A., Mariani, B., Noto, A., Rossi, F. G., & Baldini, L. (2023). Reply to “successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients-A Czech multicenter experience”: A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era. Hematological Oncology, 41(1), 213–217. https://doi.org/10.1002/hon.3079

Chicago

Cassin, Ramona, Nicolo Rampi, Cecilia Anna Fidanza, Antonio Muscatello, Bianca Mariani, Alessandro Noto, Francesca Gaia Rossi, and Luca Baldini. 2023. “Reply to ‘Successful Early Use of Anti-SARS-CoV-2 Monoclonal Neutralizing Antibodies in SARS-CoV-2 Infected Hematological Patients-A Czech Multicenter Experience’: A Case Series of SARS-CoV-2 Omicron Infection and Aggressive Lymphoma in the Sotrovimab Era.” Hematological Oncology 41 (1): 213–17. doi:10.1002/hon.3079.